- pSivida Corp Company Overview
- pSivida Corp Company Snapshot
- pSivida Corp Pipeline Products and Ongoing Clinical Trials Overview
- pSivida Corp – Pipeline Analysis Overview
- pSivida Corp - Key Facts
- pSivida Corp - Major Products and Services
- pSivida Corp Pipeline Products by Development Stage
- pSivida Corp Ongoing Clinical Trials by Trial Status
- pSivida Corp Pipeline Products Overview
- Durasert - Back Of Eye Disease
- Durasert - Back Of Eye Disease Product Overview
- Durasert - Front Of Eye Disease
- Durasert - Front Of Eye Disease Product Overview
- Durasert - Knee Osteoarthritis
- Durasert - Knee Osteoarthritis Product Overview
- Durasert - Knee Osteoarthritis Clinical Trial
- Durasert - Posterior Segment Uveitis
- Durasert - Posterior Segment Uveitis Product Overview
- Durasert - Posterior Segment Uveitis Clinical Trial
- Durasert Latanoprost Implant
- Durasert Latanoprost Implant Product Overview
- DURASERT With TKI - Wet AMD
- DURASERT With TKI - Wet AMD Product Overview
- Next Gen Duraset - Posterior Segment Uveitis
- Next Gen Duraset - Posterior Segment Uveitis Product Overview
- Tethadur System
- Tethadur System Product Overview
- pSivida Corp - Key Competitors
- pSivida Corp - Key Employees
- pSivida Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- pSivida Corp, Recent Developments
- Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
- Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
- Jul 18, 2017: Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
- Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
- Jun 22, 2017: pSivida Submits Marketing Authorization Application for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union
- Jun 13, 2017: pSivida's Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
- May 08, 2017: Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
- May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results
- May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
- May 04, 2017: pSivida Provides Update On Durasert
- Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- pSivida Corp Pipeline Products and Ongoing Clinical Trials Overview
- pSivida Corp Pipeline Products by Equipment Type
- pSivida Corp Pipeline Products by Indication
- pSivida Corp Ongoing Clinical Trials by Trial Status
- pSivida Corp, Key Facts
- pSivida Corp, Major Products and Services
- pSivida Corp Number of Pipeline Products by Development Stage
- pSivida Corp Pipeline Products Summary by Development Stage
- pSivida Corp Ongoing Clinical Trials by Trial Status
- pSivida Corp Ongoing Clinical Trials Summary
- Durasert - Back Of Eye Disease - Product Status
- Durasert - Back Of Eye Disease - Product Description
- Durasert - Front Of Eye Disease - Product Status
- Durasert - Front Of Eye Disease - Product Description
- Durasert - Knee Osteoarthritis - Product Status
- Durasert - Knee Osteoarthritis - Product Description
- Durasert - Knee Osteoarthritis - A Pilot Study of a Dexamethasone Implant System in Humans
- Durasert - Posterior Segment Uveitis - Product Status
- Durasert - Posterior Segment Uveitis - Product Description
- Durasert - Posterior Segment Uveitis - A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye
- Durasert - Posterior Segment Uveitis - A Phase III, Multi-national, Multi-center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye
- Durasert Latanoprost Implant - Product Status
- Durasert Latanoprost Implant - Product Description
- DURASERT With TKI - Wet AMD - Product Status
- DURASERT With TKI - Wet AMD - Product Description
- Next Gen Duraset - Posterior Segment Uveitis - Product Status
- Next Gen Duraset - Posterior Segment Uveitis - Product Description
- Tethadur System - Product Status
- Tethadur System - Product Description
- pSivida Corp, Key Employees
- pSivida Corp, Subsidiaries
- Glossary
- List of Figures
- pSivida Corp Pipeline Products by Equipment Type
- pSivida Corp Pipeline Products by Development Stage
- pSivida Corp Ongoing Clinical Trials by Trial Status
Summary
pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. pSivida’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company offers drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company pSivida Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
;